Deaths and disability from natalizumab are no longer tolerable: Yes

Multiple Sclerosis Journal

Volumn 18, Issue 8, 2012, Pages 1068-1069

  Duquette, Pierre ^a  

^a CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

GLATIRAMER; INTERFERON; NATALIZUMAB;

ARTICLE; BRAIN RADIOGRAPHY; COST CONTROL; DISABILITY; DISEASE COURSE; DRUG EFFICACY; DRUG TOLERABILITY; EXPANDED DISABILITY STATUS SCALE; HEALTH CARE COST; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LIVER GRAFT; LIVER NECROSIS; MORTALITY; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PROGNOSIS; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; RELAPSE; THYROID DISEASE; UNSPECIFIED SIDE EFFECT;

EID: 84864134474     PISSN: 13524585     EISSN: 14770970     Source Type: Journal    
DOI: 10.1177/1352458512451945     Document Type: Article

References (9)

1. Tremlett H, Yinshan Zhao , Devonshire V. Natural history of secondary-progressive multiple sclerosis. Mult Scler. 2008 ; 14: 314-324
2. Tremlett H, Paty D, Devonshire V. Disability progression in multiple sclerosis is slower than previously reported. Neurology. 2006 ; 66: 172-177
3. Pucci E, Giuliani G, Solari A, Simi S, Minozzi S, Di Pietrantonj C, et al. Natalizumab for relapsing remitting multiple sclerosis. Cochrane Database Syst Rev. 2011 ; 10 :
4. Fox RJ, Rudick RA. Risk stratification and patient counseling for natalizumab in multiple sclerosis. Neurology. 2012 ; 78: 436-437
5. Goodin DS, Cohen BA, O'Connor P, Kappos L, Stevens JC. Assessment: The use of natalizumab (Tysabri) for the treatment of multiple sclerosis (an evidence-based review): Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology. 2008 ; 71: 766-773
6. Keegan BM. Natalizumab for multiple sclerosis: a complicated treatment. Lancet Neurol. 2011 ; 10: 677-678
7. Rammohan KW, Ortega MR, Delgado SR, Tornes L. Disease activity return during natalizumab treatment interruption in patients with multiple sclerosis. Neurology. 2011 1930 ; 77 :
8. Tan IL, McArthur JC, Clifford DB, Major EO, Nath A. Immune reconstitution inflammatory syndrome in natalizumab-associated PML. Neurology. 2011 ; 77: 1061-1067
9. Rispens T, Vennegoor A, Wolbink GJ, Polman CH, Killestein J. Natalizumab remains detectable in patients with multiple sclerosis long after treatment is stopped.. 2012 ; 18 (6). 899-901